
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. has made significant regulatory progress with OST-HER2, enhancing its prospects for approval in treating metastatic osteosarcoma, which may lead to strong market potential. The company's management has demonstrated confidence in capturing a substantial addressable market, bolstered by a projected growth trajectory in the global veterinary oncology sector from $1.58 billion in 2024 to $4.77 billion by 2034. Furthermore, successful preliminary discussions with the NYSE and engagement with key opinion leaders, regulatory experts, and commercial manufacturers indicate a solid foundation for the operational framework of the upcoming entity focused on animal health.
Bears say
OS Therapies Inc faces significant challenges in its development pipeline due to the inherent limitations in treating osteosarcoma, which is characterized by poor responsiveness to receptor-level HER2 inhibition and other antibody-based therapies. The company's focus on a disease that is genetically unstable and immunologically “cold” raises concerns about the efficacy of its treatments and the potential market demand for these products. Furthermore, these scientific hurdles could negatively impact OS Therapies' prospects for successful clinical trials and commercialization, ultimately affecting its financial performance and stock valuation.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares